Amicus Therapeutics names new board member

Amicus Therapeutics, a biopharmaceutical company, has appointed Margaret McGlynn to its board of directors.

Most recently, Ms McGlynn served as president of vaccines and infectious diseases at Merck & Co. Ms McGlynn joined Merck in 1983 and served in a variety of marketing, sales and managed care roles.

In addition to her position at Merck, Ms McGlynn serves as a member of the board of directors for air products and chemicals. Ms McGlynn holds a BS in pharmacy and a MBA in marketing from the State University of New York at Buffalo.

John Crowley, president and CEO of Amicus Therapeutics, said: "Margie's vast industry expertise and insight will be invaluable to Amicus as we execute on our key strategic priorities and continue our focus on building shareholder value with our technologies. We are very pleased to welcome her to our board."

http://www.datamonitor.com
Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall 
not be liable for errors or delays in the content, or for any actions 
taken in reliance thereon

Related terms: ceo, chemicals, marketing, new york, pharmacy, president, sales, technology, university